319 related articles for article (PubMed ID: 28280225)
1. Role of
Houard C; Pinaquy JB; Mesguich C; Henriques de Figueiredo B; Cazeau AL; Allard JB; Laharie H; Bordenave L; Fernandez P; Vendrely V
J Nucl Med; 2017 Sep; 58(9):1414-1420. PubMed ID: 28280225
[TBL] [Abstract][Full Text] [Related]
2. Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma.
Goldman KE; White EC; Rao AR; Kaptein JS; Lien WW
Pract Radiat Oncol; 2016; 6(5):e149-e154. PubMed ID: 26948134
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy.
Day FL; Link E; Ngan S; Leong T; Moodie K; Lynch C; Michael M; Winton Ed; Hogg A; Hicks RJ; Heriot A
Br J Cancer; 2011 Aug; 105(4):498-504. PubMed ID: 21792197
[TBL] [Abstract][Full Text] [Related]
4. Role of 18F-FDG PET-derived parameters for predicting complete response to chemoradiotherapy in squamous cell anal carcinoma.
Filippi L; Fontana A; Spinelli GP; Rossi L; Bagni O
Nucl Med Commun; 2020 Oct; 41(10):1089-1094. PubMed ID: 32732599
[TBL] [Abstract][Full Text] [Related]
5. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer.
Schwarz JK; Siegel BA; Dehdashti F; Myerson RJ; Fleshman JW; Grigsby PW
Int J Radiat Oncol Biol Phys; 2008 May; 71(1):180-6. PubMed ID: 17996387
[TBL] [Abstract][Full Text] [Related]
6. Combined PET-CT and MRI for response evaluation in patients with squamous cell anal carcinoma treated with curative-intent chemoradiotherapy.
Adusumilli P; Elsayed N; Theophanous S; Samuel R; Cooper R; Casanova N; Tolan DJ; Gilbert A; Scarsbrook AF
Eur Radiol; 2022 Aug; 32(8):5086-5096. PubMed ID: 35274187
[TBL] [Abstract][Full Text] [Related]
7. Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.
Mohammadkhani Shali S; Schmitt V; Behrendt FF; Winz OH; Heinzel A; Mottaghy FM; Eble MJ; Verburg FA
Eur J Radiol; 2016 Aug; 85(8):1390-4. PubMed ID: 27423677
[TBL] [Abstract][Full Text] [Related]
8. Negative 18F-FDG-PET-CT may exclude residual or recurrent disease in anal cancer.
Teagle AR; Gilbert DC; Jones JR; Burkill GJ; McKinna F; Dizdarevic S
Nucl Med Commun; 2016 Oct; 37(10):1038-45. PubMed ID: 27341410
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer.
Gauthé M; Richard-Molard M; Fayard J; Alberini JL; Cacheux W; Lièvre A
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):63-70. PubMed ID: 27503193
[TBL] [Abstract][Full Text] [Related]
10. What
Turgeon GA; Iravani A; Akhurst T; Beaulieu A; Callahan JW; Bressel M; Cole AJ; Everitt SJ; Siva S; Hicks RJ; Ball DL; Mac Manus MP
J Nucl Med; 2019 Mar; 60(3):328-334. PubMed ID: 30030343
[TBL] [Abstract][Full Text] [Related]
11. Anal cancer chemoradiotherapy outcome prediction using
Rusten E; Rekstad BL; Undseth C; Klotz D; Hernes E; Guren MG; Malinen E
Br J Radiol; 2019 May; 92(1097):20181006. PubMed ID: 30810343
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for response evaluation in recurrent carcinoma cervix: does metabolic response predict survival?
Dhull VS; Sharma P; Sharma DN; Maharjan S; Suman Kc S; Patel C; Bal C; Kumar R
Int J Gynecol Cancer; 2014 Feb; 24(2):312-20. PubMed ID: 24407578
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic value of 18F-FDG PET/CT in recurrent germinal tumor carcinoma.
Alongi P; Evangelista L; Caobelli F; Spallino M; Gianolli L; Midiri M; Picchio M
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):85-94. PubMed ID: 28828589
[TBL] [Abstract][Full Text] [Related]
14. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of posttreatment
Lima GM; Matti A; Vara G; Dondi G; Naselli N; De Crescenzo EM; Morganti AG; Perrone AM; De Iaco P; Nanni C; Fanti S
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2139-2146. PubMed ID: 30069578
[TBL] [Abstract][Full Text] [Related]
16.
Kim SA; Roh JL; Kim JS; Lee JH; Lee SH; Choi SH; Nam SY; Kim SY
Eur J Cancer; 2017 Feb; 72():62-70. PubMed ID: 28027517
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of qualitative response assessment interpretation criteria at 18F-FDG PET-CT for predicting outcome in locally advanced cervical carcinoma treated with chemoradiotherapy.
Scarsbrook A; Vaidyanathan S; Chowdhury F; Swift S; Cooper R; Patel C
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):581-588. PubMed ID: 27738729
[TBL] [Abstract][Full Text] [Related]
18.
Avallone A; Aloj L; Pecori B; Caracò C; De Stefano A; Tatangelo F; Silvestro L; Granata V; Bianco F; Romano C; Di Gennaro F; Budillon A; Petrillo A; Muto P; Botti G; Delrio P; Lastoria S
J Nucl Med; 2019 Nov; 60(11):1560-1568. PubMed ID: 30877175
[TBL] [Abstract][Full Text] [Related]
19. Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence.
Sivarajah S; Isaac A; Cooper T; Zhang H; Puttagunta L; Abele J; Biron V; Harris J; Seikaly H; O' Connell DA
JAMA Otolaryngol Head Neck Surg; 2018 Nov; 144(11):1037-1043. PubMed ID: 30242338
[TBL] [Abstract][Full Text] [Related]
20. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
